COMPARISON OF EFFICACY OF ORAL VERSUS INTRAVENOUS DILTIAZEM(DRUG USED TO CONTROL HEART RATE) IN PATIENTS WITH RAPID IRREGULAR HEART RATE
- Conditions
- Health Condition 1: I480- Paroxysmal atrial fibrillation
- Registration Number
- CTRI/2022/11/047351
- Lead Sponsor
- AIIMS RISHIKESH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Age >18yrs
2.Patients presenting to ED of AIIMS Rishikesh with Atrial Fibrillation (AF)with rapid ventricular rate (Ventricular rate >110/min) and having received initial diltiazem iv bolus (weight based).
1.Hemodynamically unstable patients
a)Systolic BP <90mmHg
b)Acutely altered mental status
c)Signs of shock
d)Ischemic chest discomfort
e)Acute heart failure
2.Any patient requiring electrical cardioversion.
3.Patients diagnosed with acute myocardial infarction.
4.Patients already received another antiarrhythmic agent within 24 hours before inclusion in study.
5.Patients in whom oral drug cannot be administered.
6.Hepatic dysfunction
a)Decompensated chronic liver failure
b)Severe acute hepatitis
7.Patients diagnosed with pre-excitation syndromes.
8.Patients not consenting to be part of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Achievement of rate control i.e ventricular rate 110/min at 4 hours after enrolment in the study.Timepoint: 4 hour
- Secondary Outcome Measures
Name Time Method 1.Need for additional intravenous (IV) boluses of diltiazem. <br/ ><br>2.Need for switching from oral to iv infusion. <br/ ><br>3.Need for another antiarrhythmic agent for rate control. <br/ ><br>4.Need for vasopressor support. <br/ ><br>5.Need for DC Cardioversion <br/ ><br>6.Length of stay in the emergency department. <br/ ><br>7.Length of in hospital stay. <br/ ><br>8.Occurrence of any adverse effects. <br/ ><br>9.Conversion to sinus rhythm. <br/ ><br>Timepoint: 4 hour